Table 1.
ch14.18, ch14.18CHO, and Investigational anti-GD2 mAbs*.
| Antibody | Description | Features |
|---|---|---|
| Approved | ||
| ch14.18 (dinutuximab) | Chimeric (murine-human) IgG1 mAb produced in murine myeloma SP2/0 cell line | FDA- and EMA-approved for neuroblastoma† |
| ch14.18/CHO (dinutuximab beta) | Chimeric (murine-human) IgG1 mAb produced in CHO cells | EMA-approved for neuroblastoma‡ |
| Investigational | ||
| 14.18 | Murine IgG1 mAb | Lower ADCC than 14.G2a |
| 14.G2a | Murine IgG2a mAb | Used to generate ch14.18 |
| 3F8 | Murine IgG3 mAb | Large experience as single agent and in combinations |
| Hu3F8 | Humanized 3F8 mAb | Less complement activation than 3F8 |
| 131I-3F8 | Murine mAb fused with iodine 131 | Radioimmunoconjugate with radioimaging and radioimmunotherapeutic properties |
| Hu14.18-IL-2 | Humanized 14.18 mAb fused with IL-2 | Clinical trials of fusion version with IL-2 |
| Hu14.18K322A | Point mutation in hu14.18 (biologically modified from 14.G2a) | Designed to reduce complement activation and subsequent painful side effects |
| ME36.1 | Murine mAb class switched to IgG1 and IgG2a | Cross reacts with GD3 |
| 8B6 | mAb that binds to O-acetyl-GD2 antigen | May reduce painful side effects |
| L72 | Fully human IgM mAb | Produced by EBV-transformed cell lines |
ADCC, antibody-dependent cellular cytotoxicity; CHO, Chinese hamster ovary; EBV, Epstein-Barr virus; EMA, European Medicines Agency; FDA, U.S. Food and Drug Administration; mAb, monoclonal antibody.
Adapted from Keyel (75).
Indicated, in combination with granulocyte-macrophage colony-stimulating factor (GM-CSF), interleukin-2 (IL-2), and 13-cis-retinoic acid (RA), for the treatment of pediatric patients with high-risk neuroblastoma who achieve at least a partial response to prior first-line multiagent, multimodality therapy.
Indicated for the treatment of high-risk neuroblastoma in patients aged 12 months and above, who have previously received induction chemotherapy and achieved at least a partial response, followed by myeloablative therapy and stem cell transplantation, as well as patients with history of relapsed or refractory neuroblastoma, with or without residual disease. Prior to the treatment of relapsed neuroblastoma, any actively progressing disease should be stabilized by other suitable measures. In patients with a history of relapsed/refractory disease and in patients who have not achieved a complete response after first line therapy, Qarziba should be combined with interleukin-2 (IL-2).